MedTrace Logo

Treatment of Patients With Active Neurocysticercosis in Eastern Africa

NCT03834337 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2023-11-30

No results posted yet for this study

Summary

This multi-centre prospective cohort study of symptomatic patients with active neurocysticercosis (NCC) aims to identify factors related to treatment success of anthelmintic therapy.

Neurological symptom/sign and cyst resolution, quality of life, accuracy and performance of serological T. solium diagnostics and NCC-specific immunological parameter will be followed up at multiple time points in the study. The final assessment will be done six months after the end of anthelmintic treatment. This study aims to guide treatment of NCC in sub-Saharan Africa by identifying factors that are associated with treatment outcomes.

The factors that cause some people to fail complete resolution of all cysts and/or symptoms/signs are unknown.

Conditions

  • Neurocysticercosis

Sponsors & Collaborators

  • National Institute for Medical Research, Tanzania

    collaborator OTHER_GOV

  • University of Zambia

    collaborator OTHER

  • Sokoine University of Agriculture

    collaborator OTHER

  • Technical University of Munich

    lead OTHER

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • Tanzania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03834337 on ClinicalTrials.gov